PARP1 and neoplasm: Combined treatment with olaparib plus ATR inhibition with VE821 induced cell death only in ATM-deficient A549 cells, suggesting that patients with ATM-deficient tumours could benefit from a combination of PARP and ATR inhibitors [61].